Tata Consultancy Services Ltd.

BSE: 532540 | NSE: TCS
Large Cap | IT - Software
2181.45
112.40 (5.43%)
< Home < Back

TCS recognized as leader for Worldwide Life Science R&D DCT Technology Solutions

Date: 27-10-2022

Tata Consultancy Services (TCS) has been named a leader in the IDC MarketScape for Worldwide Life Science R&D Decentralized Clinical Trial (DCT) Technology Solutions. According to the report, TCS' differentiators include the breadth of DCT capabilities that it offers, the ease of implementation of its solutions, and its competitive pricing. Its value proposition for DCTs is its end-to-end integrated platform and its ecosystem play.

TCS ADD Connected Clinical Trials is a comprehensive suite of AI/ML-based platforms for decentralized trials. It provides a unified interface for patients and sites, facilitates collaboration with stakeholders such as regulators, sites, and health authorities, and enables patient-centric trials. The platform connects patients, sites, and sponsors through a variety of innovative sensors, smart medication packages, and mobile devices, to enhance trial outcomes. It caters to operations across the clinical studies lifecycle including e-consent, smart questionnaire (eCOA, diaries and surveys), an industry first supply management platform that brings together kit tracking, digital labels, and unit/dose tracking (medication adherence), and telemedicine.

The platform is comprehensive, interoperable and supports eco-system interplay, has multilingual capabilities, as well as the ability to be hosted on multi-cloud and multi-region. In addition, TCS ADD Connected Clinical Trials supports automated data collection, enables remote monitoring and oversight suitable for high frequency and a high volume of data.

TCS is an IT services, consulting and business solutions organization that has been partnering with many of the world’s largest businesses in their transformation journeys for over 50 years.